A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.
A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.
复制标题
DOI：
10.1016/j.schres.2017.01.008
复制
发表时间：
2017-07
影响因子：
4.5
通讯作者：
Penn DL
中科院分区：
文献类型：
--
作者：
Jarskog LF;Pedersen CA;Johnson JL;Hamer RM;Rau SW;Elliott T;Penn DL
精神分裂症患者的社会认知受损，这些缺陷与社会功能密切相关。催产素是一种下丘脑肽，有助于增强母婴关系，并对成人具有多种亲社会作用。这项研究检验了这样的假设：12 周的鼻内催产素将改善门诊精神分裂症和分裂情感障碍患者的社会认知功能。 68 名符合条件的参与者被随机分配使用催产素（24 IU，每天两次）或安慰剂。在基线、第 6 周和第 12 周使用情绪识别 40、Brüne 心理理论、从眼中读心测试、可信度任务和模糊意图敌意问卷来评估社会认知功能。此外，使用特定功能水平量表和角色扮演测试评估社会功能，并使用阳性和阴性综合症量表（PANSS）评估精神病理学。 55 名参与者完成了为期 12 周的试验。该研究没有发现任何证据表明催产素在社会认知方面比安慰剂具有差异优势。在次要结果中，催产素在社会功能的组成部分比安慰剂有一定的优势，尽管也有证据表明安慰剂组在角色扮演任务中优于催产素组。在预先指定的比较中，精神病理学测量没有出现组间差异，但催产素显示组内 PANSS 阴性症状显着减少，组间精神分裂症亚组阴性症状显着改善。需要进一步的测试来阐明催产素是否具有治疗精神分裂症患者的社交认知缺陷和/或阴性症状的潜力。
Social cognition is impaired in people with schizophrenia and these deficits are strongly correlated with social functioning. Oxytocin is a hypothalamic peptide that contributes to maternal infant bonding and has diverse pro-social effects in adults. This study tested the hypothesis that 12 weeks of intranasal oxytocin will improve social cognitive function in outpatients with schizophrenia and schizoaffective disorder. Sixty-eight eligible participants were randomized to oxytocin (24 IU twice daily) or placebo. Social cognitive function was assessed using the Emotion Recognition-40, Brüne Theory of Mind, Reading the Mind in the Eyes test, Trustworthiness task and Ambiguous Intentions Hostility Questionnaire at baseline, 6 weeks and 12 weeks. In addition, social function was assessed using the Specific Levels of Functioning Scale and a role-play test, and psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Fifty-five participants completed the 12-week trial. The study found no evidence for a differential advantage of oxytocin over placebo on social cognition. Among secondary outcomes, there was a modest advantage for oxytocin over placebo on a component of social functioning, although there was also evidence that the placebo group outperformed the oxytocin group on the role-play task. No between-group differences emerged on measures of psychopathology in pre-specified comparisons, but oxytocin showed significant within-group reduction in PANSS negative symptoms and significant between-group improvement in negative symptoms in the schizophrenia subgroup. Further testing is needed to clarify whether oxytocin has therapeutic potential for social cognitive deficits and/or negative symptoms in people with schizophrenia.